TilrayTLRY
About: Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.
Employees: 2,650
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
18% more repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 74
9% less call options, than puts
Call options by funds: $7.26M | Put options by funds: $8.01M
1.31% less ownership
Funds ownership: 11.12% [Q4 2024] → 9.81% (-1.31%) [Q1 2025]
6% less funds holding
Funds holding: 349 [Q4 2024] → 327 (-22) [Q1 2025]
25% less first-time investments, than exits
New positions opened: 41 | Existing positions closed: 55
55% less capital invested
Capital invested by funds: $135M [Q4 2024] → $60.4M (-$74.1M) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Piper Sandler Michael Lavery | 148%upside $1 | Neutral Maintained | 9 Apr 2025 |
Financial journalist opinion
Based on 12 articles about TLRY published over the past 30 days









